ShareI n the sterile silence of a hospital cardiology department, the profound impact of smoking on cardiovascular health is visible in every patient chart, every irregular heartbeat displayed on ...

today announced that management will participate in Stifel’s 2025 Virtual CNS Forum. Vistagen’s President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The nervous system consists of the central nervous system (brain and spinal cord) and the peripheral nervous system (motor nerves, sensory nerves, cranial and spinal nerves, autonomic ganglia ...

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART HytrulogMG patients on VYVGART achieve rapid, substantial, and sustained efficacy ...

Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency ("RF") Generator On track for Investigational Device Exemptio ...

The specific indicators of this improvement were: increased cardiac output, stroke volume, and peripheral muscle oxygenation. Although, at first glance, it is easy to overestimate the findings and ...